2 weeks Ago By ABMN Staff
Maverick Capital Ltd. increased its position in Vaxcyte, Inc. ( NASDAQ:PCVX – Free Report ) by 93.
7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 687,908 shares of the company’s stock after acquiring an additional 332,777 shares during the quarter. Maverick Capital Ltd.
owned about 0.62% of Vaxcyte worth $51,944,000 at the end of the most recent quarter. Other large investors also recently modified their holdings of the company.
Parallel Advisors LLC boosted its position in shares of Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after acquiring an additional 250 shares during the period.
Fifth Third Bancorp bought a new position in shares of Vaxcyte in the second quarter valued at approximately $35,000. Fidelis Capital Partners LLC bought a new position in shares of Vaxcyte in the first quarter valued at approximately $37,000. J.
Safra Asset Management Corp boosted its position in shares of Vaxcyte by 649.4% in the second quarter. J.
Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the period. Finally, Quest Partners LLC bought a new stake in Vaxcyte during the second quarter valued at approximately $70,000. 96.
78% of the stock is currently owned by institutional investors. Insider Buying and Selling at Vaxcyte In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $81.
17, for a total value of $649,360.00. Following the transaction, the chief financial officer now owns 96,720 shares in the company, valued at $7,850,762.
40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . In related news, CEO Grant Pickering sold 2,616 shares of the firm’s stock in a transaction on Monday, July 1st.
The stock was sold at an average price of $76.33, for a total value of $199,679.28.
Following the completion of the sale, the chief executive officer now owns 143,438 shares of the company’s stock, valued at $10,948,622.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $81.17, for a total transaction of $649,360.
00. Following the completion of the sale, the chief financial officer now owns 96,720 shares in the company, valued at approximately $7,850,762.40.
The disclosure for this sale can be found here . Insiders sold 78,283 shares of company stock valued at $7,064,138 in the last quarter. Company insiders own 3.
10% of the company’s stock. Vaxcyte Trading Down 1.8 % Vaxcyte ( NASDAQ:PCVX – Get Free Report ) last released its quarterly earnings data on Tuesday, August 6th.
The company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.
04. During the same period in the previous year, the business posted ($0.70) EPS.
As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades Several equities research analysts have issued reports on PCVX shares. Bank of America lifted their target price on shares of Vaxcyte from $101.00 to $140.
00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Mizuho lifted their target price on shares of Vaxcyte from $113.
00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Needham & Company LLC lifted their target price on shares of Vaxcyte from $95.
00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group lifted their target price on shares of Vaxcyte from $108.
00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.
com, the company has a consensus rating of “Buy” and a consensus target price of $147.50. View Our Latest Research Report on PCVX Vaxcyte Company Profile ( Free Report ) Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. Featured Articles Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Vaxcyte, Inc. ( NASDAQ:PCVX – Free Report ). Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.
com's FREE daily email newsletter ..
